对伊布替尼有反应的慢性淋巴细胞白血病中的膜性肾病：一例报告。
Membranous nephropathy in chronic lymphocytic leukemia responsive to ibrutinib: A case report.
作者信息
Turcotte Anna-Eve, Glass William F, Lin Jamie S, Burger Jan A
机构信息
Section of Nephrology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.
Department of Pathology and Laboratory Medicine, University of Texas Health Science Center McGovern Medical School, Houston, TX, United States of America.
出版信息
Leuk Res Rep. 2023 Jun 20;20:100377. doi: 10.1016/j.lrr.2023.100377. eCollection 2023.
Membranous nephropathy (MN) is an uncommon renal presentation in patients with chronic lymphocytic leukemia (CLL), and as such, there is no standard therapy for these patients. A few cases of MN in CLL have been described with varying success in MN treatment involving alkylating agents and fludarabine. Here we report the first case of MN in a patient with CLL treated with ibrutinib with complete renal response. This presentation underlines the importance of recognizing rare glomerular diseases that may occur with CLL and offers a new therapeutic avenue to the treatment of CLL-associated MN.
膜性肾病（MN）在慢性淋巴细胞白血病（CLL）患者中是一种不常见的肾脏表现，因此，对于这些患者没有标准的治疗方法。已有少数CLL合并MN的病例报道，使用烷化剂和氟达拉滨治疗MN取得了不同程度的成功。在此，我们报告首例使用伊布替尼治疗且肾脏完全缓解的CLL合并MN患者。该病例强调了认识CLL可能伴发的罕见肾小球疾病的重要性，并为CLL相关MN的治疗提供了一条新的治疗途径。
Zotero 插件